Physician profile
Simon S Lipetz
NPI 1710967393
$15,715.63
in general payments reported to CMS, 2019-2025
47 companies · $2,908 in 2025
The $2,908 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,050 · 2020: $1,741 · 2021: $2,778 · 2022: $2,670 · 2023: $1,051 · 2024: $2,519 · 2025: $2,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,477.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,949.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,755.05 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,875.93 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $921.26 | 2019-2025 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $892.69 | 2021-2025 | Dupixent |
| Genzyme Corporation | $780.00 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $659.00 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $616.45 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $466.16 | 2020-2025 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $442.15 | 2020-2021 | |
| Pfizer INC. | $395.72 | 2020-2025 | |
| Amarin Pharma, INC. | $327.14 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $218.17 | 2019-2025 | Camzyos, Eliquis |
| Cequr Corporation | $217.28 | 2022-2023 | Cequr Simplicity |
| Amryt Pharma Holdings LTD | $150.01 | 2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Lipetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.